# D3

> D3 is a VC fund in Tokyo backing Biotechnology, Therapeutics and Manufacturing. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tokyo, Japan
- Total investments: 12
- Last investment: Apr 2026
- Lead investor: 58%
- Last updated: Aug 2026
- Website: https://www.d3growth.com

D3 is a VC fund in Tokyo focused on Biotechnology and Therapeutics. D3 LLC is providing management consultancy and financial services.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.6M–$2.8M |
| Series A | $690k–$51M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 33% |
| Therapeutics | 3 | 25% |
| Manufacturing | 3 | 25% |
| Medical | 2 | 17% |
| Software | 2 | 17% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 50% |
| Seed | 3 | 25% |
| Series B | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 6 | 50% |
| United States | 2 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neumo | Neumo is a musical education-based firm that offers pitch measurement courses, programs, consulting, and tests. |  | Series A | Apr 23, 2026 |  |
| RevolKa | RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $1.5M | Series A | May 20, 2025 |  |
| Neros Technologies | Neros Technologies provides autonomous drone services. | $35M | Series A | Mar 17, 2025 |  |
| Alpha Fusion | Alpha Fusion produces astatine based radiopharmaceuticals for targeted alpha therapy. | $6.9M | Series B | Oct 08, 2024 |  |
| Swarmer | Swarmer is an AI based mission control center for coordinated drones that acts as Firmware for video streaming, logging and monitoring. | $2.7M | Seed | Sep 01, 2024 |  |
| RevolKa | RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $690.2K | Series A | Aug 29, 2024 |  |
| Cyto-Facto | Cyto-Facto is a biotechnology company that develops and manufactures CAR-T cell therapies and mesenchymal stem cell products. | $7.6M | Series A | Apr 22, 2024 |  |
| RevolKa | RevolKa manufactures bio-products pharmaceuticals intended to serve the healthcare sector. | $1M | Series A | Feb 01, 2024 |  |
| Shinobi Therapeutics | Shinobi Therapeutics is a biotechnology business that is working on a novel class of immune-evasive iPSC-derived cell treatments. | $51M | Series A | Dec 12, 2023 |  |
| B4A | B4A provides DX tool for medical clinics that helps with reservation, customer management, and data analysis. | $2M | Series A | Sep 27, 2023 |  |

10 of 12 investments shown.

## Co-investors
- [Deepcore](https://shizune.co/investors/profile/deepcore) — VC Fund, 4 deals together
- [i-nest capital](https://shizune.co/investors/profile/i-nest-capital) — VC Fund, 2 deals together
- [Kobe University Capital](https://shizune.co/investors/profile/kobe-university-capital-71a5) — VC Fund, 2 deals together
- [Tohoku University Venture Partners](https://shizune.co/investors/profile/tohoku-university-venture-partners) — VC Fund, 2 deals together
- [Aerion Partners](https://shizune.co/investors/profile/aerion-partners) — VC Fund, 1 deal together
- [Animal Spirits Ltd.](https://shizune.co/investors/profile/animal-spirits-ltd) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Japan](https://shizune.co/investors/biotechnology-investors-japan)
- [Biotechnology VC Funds in Japan](https://shizune.co/investors/biotechnology-vc-funds-japan)
- [Biotech VC Funds in Japan](https://shizune.co/investors/biotech-vc-funds-japan)
- [Health Care Investors in Japan](https://shizune.co/investors/health-care-investors-japan)
- [Health Care VC Funds in Japan](https://shizune.co/investors/health-care-vc-funds-japan)

## FAQ

### What does D3 invest in?

D3 invests primarily in Biotechnology, Therapeutics and Manufacturing startups, most often at Series A and Seed stage. Most of the 12 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is D3's check size?

D3 typically joins rounds of $1.6M–$2.8M at Seed and $690k–$51M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds D3 participates in.

### When did D3 last invest?

The most recent investment recorded for D3 closed in Apr 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co